Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Rilogrotug

Preclinical

AAVEO Pharmaceuticals, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cachexia; CancerNot yet recruiting

Cachexia; CancerPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2031

PreclinicalNot yet recruiting

Cachexia; Cancer

NCT07888075

Clinical

Trials by Indication[1]

Cachexia; Cancer1 trial

A Phase 2/3 Randomized, Double-Blind Study of Rilogrotug Versus Placebo in the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

Not yet recruiting·AAVEO Pharmaceuticals, Inc.·Preclinical·NCT07888075·950 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rilogrotug. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rilogrotug. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AVEO Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AAVEO Pharmaceuticals, Inc.

Related News